263
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Expedient Synthesis and Antitumor Evaluation of Novel Azaheterocycles from Thiazolylenaminone

ORCID Icon, &
Pages 2123-2143 | Received 02 Dec 2021, Accepted 01 Feb 2022, Published online: 12 Feb 2022
 

Abstract

Thiazole is a functional group used in cancer treatment modalities in synthetic and natural antitumor medications. In this context, convenient synthesis of new 5-heteroaryl-thiazoles is described via reactions of thiazolylenaminone with sulfanilamide, sulfathiazole, hydrazine hydrate, phenylhydrazine, hydroxylamine, guanidine, aminoazoles, β-dicarbonyl compounds, and diazotized aminoazoles. The constitution of the constructed thiazoles was avowed by elemental analyses and spectral data as well as alternative syntheses wherever possible. Thiazoles were also tested for their antitumor activity toward human cancer cell lines (MCF-7, HCT-116, and HepG-2) and one normal cell line (REP1). Among the synthesized thiazoles, compounds 6, 19, and 23a showed high potent antitumor profiles toward cancer cell lines and found no evidence of human toxicity.

Acknowledgements

The authors are grateful for the administrative and technical assistance provided by King Khalid University in Abha, Saudi Arabia.

Additional information

Funding

The authors thank the Deanship of Scientific Research at King Khalid University for financing this research through a research group project with grant number RGP.1/32/42.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.